DR. COLIN MICHAEL MCHUGH MD
Prescription History 1659614972
Internal Medicine - Hematology & Oncology in Rochester, NY


Quality Rating: 76.84 out of 100 score

NPI Status: Active since April 04, 2013

Contact Information

1000 SOUTH AVE BLDG LEVEL3
ROCHESTER, NY
ZIP 14620
Phone: (585) 475-9411

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. COLIN MICHAEL MCHUGH MD, an active Hematology & Oncology specialist practicing in Rochester, NY. Our medical registry currently tracks 21 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 584 documented patient claims. Among these therapy options, the most frequently utilized medication is Prochlorperazine Maleate, which accounts for 53 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 43
30-Day Fills 45.0
Days Supply 1,335
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills46.7
Peer Average Days Supply1,392
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $211,493.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,918.46

State Avg Cost Per Claim

$3,990.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 20.0
Days Supply 600
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills39.5
Peer Average Days Supply1,106
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $226.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.84

State Avg Cost Per Claim

$49.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 51
30-Day Fills 51.0
Days Supply 1,530
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.3
Peer Average Days Supply995
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 59.4% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $749,287.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,691.90

State Avg Cost Per Claim

$13,727.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Deferasirox

Generic Formulation: DeferasiroxSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NY State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.6
Peer Average Days Supply617
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,313.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$109.42

State Avg Cost Per Claim

$3,585.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.

Therapeutic Applications

This medication is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia). It works by binding to iron, allowing the body to pass extra iron out in the stool. Deferasirox belongs to a class of drugs known as iron-chelating agents. Frequent blood transfusions are often needed in certain types of blood diseases (such as sickle cell disease, anemia). Blood transfusions have very helpful benefits, but they can cause the body to hold on to too much iron. The extra iron can build up in the body and cause problems such as heart failure, liver disease, and diabetes. Getting rid of extra iron can decrease the risk of these diseases.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 26.0
Days Supply 449
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.5
Peer Average Days Supply434
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $384.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.02

State Avg Cost Per Claim

$16.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 28.0
Days Supply 840
NY State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills127.9
Peer Average Days Supply3,554
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.5% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,729.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$683.87

State Avg Cost Per Claim

$816.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 18.0
Days Supply 540
NY State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills113.9
Peer Average Days Supply3,301
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $202.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.91

State Avg Cost Per Claim

$17.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 67.1
Days Supply 2,012
NY State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills59.8
Peer Average Days Supply1,753
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,045.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.04

State Avg Cost Per Claim

$32.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 812
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.6
Peer Average Days Supply768
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $461,915.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,928.11

State Avg Cost Per Claim

$14,520.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
NY State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply738
Conservative Utilization

This provider writes prescriptions for this formulation 40.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,598.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,199.88

State Avg Cost Per Claim

$3,439.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 1,208
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.9
Peer Average Days Supply908
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 32.3% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $441,328.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,764.11

State Avg Cost Per Claim

$14,730.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Inlyta

Generic Formulation: AxitinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
NY State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.7
Peer Average Days Supply583
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $231,072.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$21,006.56

State Avg Cost Per Claim

$16,200.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.

Therapeutic Applications

This medication is used to treat kidney cancer. Axitinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as tyrosine kinase inhibitors.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 26
30-Day Fills 52.0
Days Supply 1,560
NY State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills106.0
Peer Average Days Supply3,158
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $648.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.93

State Avg Cost Per Claim

$29.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Lidocaine-Prilocaine

Generic Formulation: Lidocaine/PrilocaineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 328
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply681
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $298.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.60

State Avg Cost Per Claim

$23.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical local anesthetic preparation that is composed of a mixture of lidocaine and prilocaine. It is used to provide anesthesia during minor surgery and for the treatment of PREMATURE EJACULATION.

Therapeutic Applications

This medication contains 2 amide-type local anesthetics, lidocaine and prilocaine. It is used on normal, unbroken skin or on the outer genital area to prevent pain before certain procedures such as inserting a needle, skin grafts, or skin laser surgery. It works by temporarily numbing the skin and surrounding area. Do not use this product in the ears. If this product alone cannot completely numb the area being treated, it may be used to numb the area before a lidocaine injection is given to provide enough pain relief for certain procedures (such as removal of genital warts).

Lonsurf

Generic Formulation: Trifluridine/Tipiracil HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
NY State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.0
Peer Average Days Supply418
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $119,142.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,928.51

State Avg Cost Per Claim

$11,694.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as stomach, colon/rectum). It works by slowing or stopping the growth of cancer cells.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 46
30-Day Fills 46.5
Days Supply 442
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.2
Peer Average Days Supply290
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 91.7% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $364.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.91

State Avg Cost Per Claim

$9.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 311
NY State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills46.0
Peer Average Days Supply929
Conservative Utilization

This provider writes prescriptions for this formulation 48.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $380.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.52

State Avg Cost Per Claim

$25.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.4
Days Supply 688
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,023
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $184.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.73

State Avg Cost Per Claim

$6.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 53
30-Day Fills 53.0
Days Supply 413
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.0
Peer Average Days Supply376
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 103.8% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $878.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.57

State Avg Cost Per Claim

$19.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Promacta

Generic Formulation: Eltrombopag OlamineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 24.0
Days Supply 720
NY State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.3
Peer Average Days Supply573
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 27.8% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $160,925.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,996.76

State Avg Cost Per Claim

$12,199.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 37
30-Day Fills 37.0
Days Supply 1,110
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply971
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $491,741.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,290.30

State Avg Cost Per Claim

$13,202.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. COLIN MICHAEL MCHUGH MD provides transparency into local medical care patterns within Rochester, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.